Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?
Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.
BSX - Boston Scientific Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$68.67
DETAILS
HIGH:
$112.00
LOW:
$50.00
MEDIAN:
$65.00
CONSENSUS:
$68.67
UPSIDE:
43.84%
Stock News
Bear of the Day: Boston Scientific (BSX)
Boston Scientific ( BSX ) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories. On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year.
First National Bank of Mount Dora Trust Investment Services Takes Position in Boston Scientific Corporation $BSX
First National Bank of Mount Dora Trust Investment Services purchased a new stake in Boston Scientific Corporation (NYSE: BSX) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 134,736 shares of the medical equipment provider's stock, valued at approximately $8,455,000. Boston
Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More
After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.
Bank of America Corp DE Has $1.43 Billion Stock Holdings in Boston Scientific Corporation $BSX
Bank of America Corp DE trimmed its position in Boston Scientific Corporation (NYSE: BSX) by 9.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,756,646 shares of the medical equipment provider's stock after selling 2,358,539 shares during the quarter. Bank
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.
Boston Scientific: Attempting The 2027 Reset
Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative earnings revisions stabilize. BSX has reset expectations, slashing guidance and acknowledging competitive pressures, particularly in WATCHMAN and electrophysiology segments. Valuation is now attractive at 13.7x forward earnings, with further upside contingent on management halting guidance cuts and delivering execution consistency.
Boston Scientific Q2 Earnings Call Highlights
Boston Scientific NYSE: BSX reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competitive pressure in U.S. electrophysiology.
Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional Cardiology and Neuromodulation
Organic Sales Growth: 7% in Q2 2026, driven by Interventional Cardiology, Endoscopy, and Neuromodulation.Adjusted EPS: $0.86, a 15% increase, exceeding guidance
Boston Scientific beats second quarter expectations, raises full-year outlook
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus estimate, while revenue reached $5.442 billion, compared with analyst expectations of $5.37 billion.
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript
Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific Cuts Forecast on Product Slowdown and Competition
Boston Scientific Corporation (NYSE:BSX) stock is trading lower after the company cut its fiscal 2026 outlook, citing pressures on the Watchman and EP markets.
Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.75 per share a year ago.
Boston Scientific beats second quarter expectations, raises full-year outlook
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while...
Boston Scientific Cuts Outlook Ahead of Restructuring
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
Boston Scientific trims annual profit forecast on softer Watchman device demand
Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
Is Boston Scientific Corp (BSX) Undervalued Despite Revenue of $5.442 Billion and EPS of $0.61? GF Score: 74/100, 56.5% Undervalued
Boston Scientific Corp (BSX) released its 8-K filing on July 29, 2026, highlighting a solid quarter with net sales of $5.442 billion, a 7.5% increase compared t
Price Targets
Boston Scientific price target lowered to $70 from $85 at RBC Capital
$70.00
(was $44.80)
Shagun Singh
·
RBC Capital
Boston Scientific price target lowered to $67 from $74 at UBS
$67.00
(was $44.90)
UBS
Boston Scientific price target lowered to $60 from $75 at Deutsche Bank
$60.00
(was $44.93)
Pito Chickering
·
Deutsche Bank
Boston Scientific price target lowered to $56 from $64 at Baird
$56.00
(was $46.04)
Robert W. Baird
Boston Scientific price target lowered to $66 from $70 at Canaccord
$66.00
(was $46.04)
Canaccord Genuity
Boston Scientific price target lowered to $50 from $55 at Wells Fargo
$50.00
(was $46.04)
Wells Fargo
Boston Scientific price target lowered to $60 from $74 at Leerink
$60.00
(was $46.04)
Leerink Partners
Boston Scientific (BSX) PT Lowered to $57 at Raymond James
$57.00
(was $46.04)
Jayson Bedford
·
Raymond James
Boston Scientific (BSX) PT Lowered to $60 at BTIG
$60.00
(was $46.04)
Marie Thibault
·
BTIG
Boston Scientific price target lowered to $60 from $65 at Stifel
$60.00
(was $46.55)
Rick Wise
·
Stifel Nicolaus
Boston Scientific assumed with a Buy at UBS
$74.00
(was $45.51)
UBS
Boston Scientific price target lowered to $85 from $90 at Oppenheimer
$85.00
(was $45.88)
Oppenheimer
Boston Scientific price target lowered to $62 from $64 at Truist
$62.00
(was $44.59)
Truist Financial
Boston Scientific price target lowered to $70 from $90 at Mizuho
$70.00
(was $42.63)
Anthony Petrone
·
Mizuho Securities
Boston Scientific price target lowered to $85 from $100 at RBC Capital
$85.00
(was $44.72)
Shagun Singh
·
RBC Capital
Boston Scientific (BSX) PT Lowered to $57 at Needham
$57.00
(was $45.30)
Mike Matson
·
Needham
Boston Scientific price target lowered to $65 from $78 at Evercore ISI
$65.00
(was $44.55)
Evercore ISI
Boston Scientific price target lowered to $65 from $75 at Stifel
$65.00
(was $44.46)
Stifel Nicolaus
Boston Scientific price target lowered to $65 from $90 at Piper Sandler
$65.00
(was $47.17)
Piper Sandler
Boston Scientific price target lowered to $64 from $85 at Truist
$64.00
(was $49.34)
Truist Financial